Drug intelligence / Profile preview

PF-07985631

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

PF-07985631 is an investigational drug being developed by Pfizer for the potential treatment of IgA nephropathy, a chronic kidney disease. The drug is currently in Phase 1 clinical trials to assess its safety and pharmacological effects in healthy adults and patients. The mechanism of action has not been publicly disclosed. The compound is administered either as a subcutaneous injection or intravenous infusion. As of now, there is no information available on brand names, detailed mechanism of action, or approval status for other indications[1][3][5][7][9][10].

Beyond the preview

Go deeper on PF-07985631.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07985631.

Explore the full profile